Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 201

Next Previous
Drug Profile

AB 201

Alternative Names: AB201-Oruka Therapeutics; NAPc2; Nematode Anticoagulant Protein c2; Recombinant NAPc2; Recombinant Nematode Anticoagulant c2; rNAPc2

Latest Information Update: 03 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dendreon Corporation
  • Developer Oruka Therapeutics
  • Class Anti-inflammatories; Anticoagulants; Antivirals; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Blood coagulation disorders; COVID 2019 infections
  • No development reported Marburg virus disease
  • Discontinued Acute coronary syndromes; Colorectal cancer; Deep vein thrombosis; Disseminated intravascular coagulation; Ebola virus infections

Most Recent Events

  • 29 Aug 2024 ARCA biopharma Inc has merged with Oruka Therapeutics to form Oruka Therapeutics
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Marburg virus disease in USA (Parenteral)
  • 31 Mar 2022 Efficacy and safety data from phase a phase IIb/III ASPEN-COVID-19 trial in COVID-2019 infections and Blood coagulation disorders released by ARCA biopharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top